Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit

Traders Union
All News
Companies
Corbus spotlights CRB-913 at BMO

Top Stories

Editors' Picks

Crypto

Financial News

Currencies

Market Voices

Companies

Regulators

Central Banks

Olesia Kramarenko

23.03.2026

Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit — Corbus spotlights CRB-913 at BMO

Corbus Pharmaceuticals Holdings, Inc. will participate in a panel at the BMO 2026 Metabolic Health Summit, focusing on its investigational therapy CRB-913.

The orally delivered CB1 inverse agonist, described as highly peripherally restricted, targets the treatment of obesity and is expected to draw attention from metabolic disease researchers at the event. The panel will provide insights into early development and the potential impact of CRB-913 on obesity therapeutics. The summit takes place tomorrow, March 24th, offering further details to stakeholders and the wider scientific community.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Corbus Pharmaceuticals recently reported financial results for the fourth quarter and full year 2025. In addition to its metabolic disease programs, the company continues early-stage development of CRB-701 targeting advanced Nectin-4 solid tumors. These updates highlight Corbus’s ongoing focus on pipeline advancement across multiple therapeutic areas.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

By Pavlo Kot
10 hours ago

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

Editors' Picks

Blockchain nation in crisis: How a power struggle split Liberland

By Pavlo Kot
Yesterday

Blockchain nation in crisis: How a power struggle split Liberland

Editors' Picks

Shifting priorities: Governments back mining as businesses turn to AI

By Eugene Komchuk
19.06.2026

Shifting priorities: Governments back mining as businesses turn to AI

Editors' Picks

All Editors' Top Picks

Latest Corbus News

Corbus Pharmaceuticals Holdings, Inc. unveils updated Phase 1/2 CRB-701 data at ASCO26

By Mikhail Vnuchkov
31.05.2026

Corbus Pharmaceuticals Holdings, Inc. unveils updated Phase 1/2 CRB-701 data at ASCO26

Companies

CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc.

By Mikhail Vnuchkov
26.05.2026

CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc.

Companies

Corbus Pharmaceuticals Holdings, Inc. appoints Nishant Saxena as chief business officer and schedules data call on CRB-701

By Parshwa Turakhiya
21.05.2026

Corbus Pharmaceuticals Holdings, Inc. appoints Nishant Saxena as chief business officer and schedules data call on CRB-701

Companies

All Corbus News

Pavlo Kot
10 hours ago

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

Pavlo Kot
Yesterday

Blockchain nation in crisis: How a power struggle split Liberland

Eugene Komchuk
19.06.2026

Shifting priorities: Governments back mining as businesses turn to AI

Mikhail Vnuchkov
18.06.2026

Intel's comeback: Apple, Trump and the AI bet

Oleg Tkachenko
17.06.2026

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Dmytro Kharkov
11 min ago

AI trade could see correction and recovery, Phil Rosen notes

Parshwa Turakhiya
36 min ago

Twelve stocks chosen to be held until June 2027, Amit Kukreja reveals

Yaroslav Dmytrenko
36 min ago

Robert Breedlove: Envy is a primary force in Bitcoin community dynamics

Hanna Syniavska
36 min ago

Keeping bitcoin in cold storage shields owners from losses, Jack Mallers argues

Andreas Kristo
46 min ago

U.S. per capita GDP gap widens from $10,000 to $20,000, Noah Smith notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
10 hours ago

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

Pavlo Kot
Yesterday

Blockchain nation in crisis: How a power struggle split Liberland

Blockchain nation in crisis: How a power struggle split Liberland

Andrey Mastykin
19.06.2026

Iran tightens rules for Hormuz ship transit

Iran tightens rules for Hormuz ship transit

Hanna Syniavska
19.06.2026

U.S.-Iran talks postponed as truce outlook dims

U.S.-Iran talks postponed as truce outlook dims

Olga Shendetskaya
19.06.2026

Oil gains after new U.S.-Iran talks are called off

Oil gains after new U.S.-Iran talks are called off

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft under pressure as technical picture remains weak

Anton Kharitonov
Now

Apple consolidates after AI rally as investors await new growth catalyst

Anton Kharitonov
Now

Bitcoin struggles for direction amid macroeconomic uncertainty

Anton Kharitonov
Now

WTI recovers after selloff as downside risks remain

Anton Kharitonov
Now

Natural gas maintains upward bias amid supply risks and seasonal demand

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.